Ratings of the last 12 months
This list shows every rating MEQIRI has published for a stock, an ETF or a coin, and every change between Strong, Neutral and Weak. For stocks it also shows every valuation signal and its changes.
Counted from the public launch on 7 Nov 2026.
- Price target: none, MEQIRI does not give price targets.
- Fair value: for the valuation signal, that day's fair value, converted like the price. An estimate from the disclosed model, not a price target.
- Validity: until the rating or the valuation signal changes, time horizon about 12 months, recalculated every night.
- Price: last close before publication, converted into dollars at that day's ECB rate; ETFs in euros.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
4 entries
- IRadimed Corporation12 Nov 2026Valuation signal Fairly valued (Before Overvalued), Fair value $61.04, $86.58
- IRadimed Corporation9 Nov 2026Valuation signal Overvalued (Before Fairly valued), Fair value $60.40, $86.31
- IRadimed Corporation7 Nov 2026Strong (first rating), Score 77, $86.31
- IRadimed Corporation7 Nov 2026Valuation signal Fairly valued (first signal), Fair value $60.63, $86.31
| Date | Security | Rating | Before | Score | Fair value | Price |
|---|---|---|---|---|---|---|
| 12 Nov 2026 | IRadimed Corporation IRMD | Valuation signalFairly valued | Overvalued | $61.04 | $86.58 | |
| 9 Nov 2026 | IRadimed Corporation IRMD | Valuation signalOvervalued | Fairly valued | $60.40 | $86.31 | |
| 7 Nov 2026 | IRadimed Corporation IRMD | Strong | first rating | 77 | $86.31 | |
| 7 Nov 2026 | IRadimed Corporation IRMD | Valuation signalFairly valued | first signal | $60.63 | $86.31 |
Legal basis: Article 4(1)(i) of Delegated Regulation (EU) 2016/958.
To the disclosures